1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sri Lanka Pharmaceuticals and Healthcare Report Q4 2016

Sri Lanka Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 71 pages

Includes 3 FREE quarterly updates


BMI View: Sri Lanka's pharmaceutical and healthcare markets will continue to expand over the next 10 years driven by economic development. Despite an increased level of fiscal tightening in the coming quarters, healthcare system strengthening and facilities upgrade will remain a policy priority. We expect growing demand for healthcare and medical treatment of chronic diseases to create commercial opportunities for drugmakers and medical operators, although the government's pro-generic drugs stance and low spending per capita on medicine will continue to tarnish the market potential appeal to innovative drugmakers.

Headline Expenditure Projections
- Pharmaceuticals: LKR82.88bn (USD610mn) in 2015 to LKR90.57bn (USD610mn) in 2016; +9.3 in local currency terms and +0.4 in US dollar terms. Forecast broadly in line with last quarter.
- Healthcare: LKR273.32bn (USD2.01bn) in 2015 to LKR293.79bn (USD1.99bn) in 2016; +7.5 in local currency terms and -1.2 in US dollar terms. Forecast revised downwards from last quarter.

Table Of Contents

Sri Lanka Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Sri Lanka 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 17
Sri Lanka 18
Pharmaceutical Trade Forecast 20
Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2014-2020) 22
Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka 2014-2020) 22
Industry Risk Reward Indices 23
Asia Pacific Risk/Reward Index - Q4 2016 23
Sri Lanka - Risk/Reward Index 30
Rewards 30
Risks 30
Regulatory Review 31
Intellectual Property Issues 35
Pricing And Reimbursement Regimes 36
Market Overview 38
Healthcare Sector 39
Clinical Trials 42
Epidemiology 43
Competitive Landscape 47
Research-Based Industry 47
Table: Multinational Market Activity 48
Pharmaceutical Distribution 49
Pharmaceutical Retail Sector 50
Company Profile 51
GlaxoSmithKline 51
Hemas Holdings 54
State Pharmaceuticals Corporation (SPC) 57
Demographic Forecast 60
Demographic Outlook 60
Table: Population Headline Indicators (Sri Lanka 1990-2025) 61
Table: Key Population Ratios (Sri Lanka 1990-2025) 61
Table: Urban/Rural Population and Life Expectancy (Sri Lanka 1990-2025) 62
Table: Population By Age Group (Sri Lanka 1990-2025) 62
Table: Population By Age Group % (Sri Lanka 1990-2025) 63
Glossary 65
Methodology 67
Pharmaceutical Expenditure Forecast Model 67
Healthcare Expenditure Forecast Model 67
Notes On Methodology 68
Risk/Reward Index Methodology 69
Index Overview 70
Table: Pharmaceutical Risk/Reward Index Indicators 70
Indicator Weightings 71

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.